Skip to main content
. 2009 Jul 30;8:52. doi: 10.1186/1476-4598-8-52

Table 1.

Antibodies

Antibody Source
anti-MNF116 cytokeratin mAb) (clone MNF116, Dako; Glostrup, Denmark

anti-AE1/AE3 cytokeratin mAb (clone AE1/AE3, Dako)

anti-CD66e mAb (clone 12-140-10, Novocastra; Newcastle, UK)

anti-EMA mAb (clone GP1.4, Novocastra)

anti-vimentin mAb (clone V9, Novocastra)

anti-PLAP mAb (clone 8A9, Novocastra)

anti-beta HCG mAB (Novocastra)

anti-NSE mAb (clone 5E2, Novocastra)

anti-GFAP mAb (clone GA5, Novocastra)

anti-desmin mAb (clone DE-R-11, Novocastra)

anti-Ki 67 mAb (clone MIB-1, Dako)

anti-CD31 mAb (clone JC70A, Dako)

anti-CD45 (clone T29/33, Dako)

anti-CD68 mAb (clone KP1, Dako)

anti-CD117 polyclonal Ab (Dako)

p145 human c-kit protein (Oncogene, Boston, MA, USA)

CD30 (Clone BER-H2)Dako

S100 Polyclonal Ab, Dako

CD3 Polyclonal Ab, Dako

CD20 Clone L26, Dako

CD45 Clone T29/33, Dako

CD56 Clone CD564, Novocastra

Synaptophysin Clone SY38, Dako

Chromogranin A Clone DAK-A3, Dako
HHS Vulnerability Disclosure